Drs Park and Sonpavde discuss findings from the phase 1 DAD trial, as well as a schema for the frontline management of metastatic urothelial carcinoma.
Oncology Unplugged With Dr Chandler Park
Advertisement
Drs Park and Sonpavde discuss the CheckMate901 trial, which showed survival improvements with nivolumab plus chemotherapy in metastatic urothelial cancer.
Drs Park and Sonpavde emphasize their insights on the topline data from the EV-302 trial of enfortumab vedotin plus pembrolizumab in urothelial carcinoma.
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Fast Track Designation to LYT-200 in R/R High-Risk MDS
2
Japan Approves Subcutaneous Pembrolizumab for All Approved Pembrolizumab Indications
3
NAPISTAR-1-01 Data Support Rapid TUB-040 Development in Biomarker-Unrestricted Ovarian Cancer
4
Making Invisible Cancers Visible: Study Suggests a New Route to Turn ‘Cold’ Tumors ‘Hot’
5